70.83
前日終値:
$69.80
開ける:
$70.96
24時間の取引高:
1.32M
Relative Volume:
2.05
時価総額:
$4.50B
収益:
-
当期純損益:
$-159.39M
株価収益率:
-20.01
EPS:
-3.5401
ネットキャッシュフロー:
$-105.22M
1週間 パフォーマンス:
+3.26%
1か月 パフォーマンス:
+825.95%
6か月 パフォーマンス:
+1,101%
1年 パフォーマンス:
+498.77%
Abivax Adr Stock (ABVX) Company Profile
ABVX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ABVX
Abivax Adr
|
70.83 | 5.25B | 0 | -159.39M | -105.22M | -3.5401 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2025-03-20 | 開始されました | Morgan Stanley | Equal-Weight |
2024-12-04 | 開始されました | JMP Securities | Mkt Outperform |
2024-07-29 | 開始されました | Laidlaw | Buy |
2024-05-20 | 開始されました | BTIG Research | Buy |
2024-04-29 | 開始されました | Guggenheim | Buy |
2024-04-29 | 開始されました | Piper Sandler | Overweight |
2023-11-14 | 開始されました | Leerink Partners | Outperform |
2023-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Abivax Adr (ABVX) 最新ニュース
Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax - Defense World
Lifesci Capital Brokers Lift Earnings Estimates for Abivax - Defense World
Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $78.75 - Defense World
Abivax SA Announces $608.6 Million Public Offering of ADSs - The Globe and Mail
Abivax (NASDAQ:ABVX) Reaches New 52-Week High on Analyst Upgrade - Defense World
Abivax SA Stock Surges on Promising Drug Results - TipRanks
Abivax (NASDAQ:ABVX) Trading 577.5% Higher on Analyst Upgrade - Defense World
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Abivax ADR Shows Rising Price Performance With Jump To 99 RS Rating - Investor's Business Daily
Abivax (NASDAQ:ABVX) Hits New 52-Week High on Analyst Upgrade - Defense World
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris - GlobeNewswire Inc.
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results - Investor's Business Daily
10 Best First Jobs for Aspiring CEOs - inkl
Prologis Inc (PLD) Stock: Navigating Drops and Gains - investchronicle.com
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod - TipRanks
Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks
Harmony Gold Mining ADR Shows Market Leadership With Jump To 82 RS Rating - inkl
Grid Metals (CVE:GRDM) Shares Up 44.4% – Here’s What Happened - Defense World
The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com
Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analyst Coverage Updates - The Globe and Mail
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease - TipRanks
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks
Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Galapagos (GLPG) and Tenet Healthcare (THC) - The Globe and Mail
European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize
Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks
Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks
Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks
Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks
Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks
Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister
Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks
Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks
Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks
Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance
Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily
Abivax Adr (ABVX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):